NCT02504541View on ClinicalTrials.gov

Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism

PHASE3CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Hypogonadism
Interventions
COMBINATION_PRODUCT

Testosterone enanthate auto-injector

Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels

Trial Locations (20)

Unknown

Birmingham

Mobile

Tucson

San Diego

Aventura

Brandon

Jacksonville

Shreveport

Elkridge

Garden City

New York

Columbus

Franklin

Medford

Charleston

Greer

Hurst

West Valley City

Olympia

Renton

Sponsors
All Listed Sponsors
lead

Antares Pharma Inc.

INDUSTRY

NCT02504541 - Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism | Biotech Hunter | Biotech Hunter